---
title: "Disc Medicine (IRON) Receives a Buy from H.C. Wainwright"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285413168.md"
description: "H.C. Wainwright analyst Douglas Tsao has reiterated a Buy rating on Disc Medicine (IRON) with a price target of $118.00. Tsao, who focuses on the Healthcare sector, has an average return of 21.2% and a 52.10% success rate on his stock recommendations. Disc Medicine currently holds a Strong Buy consensus among analysts, with a price target consensus of $97.67."
datetime: "2026-05-06T16:36:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285413168.md)
  - [en](https://longbridge.com/en/news/285413168.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285413168.md)
---

# Disc Medicine (IRON) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Disc Medicine today and set a price target of $118.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Tsao covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Rezolute, and Xenon. According to TipRanks, Tsao has an average return of 21.2% and a 52.10% success rate on recommended stocks.

Disc Medicine has an analyst consensus of Strong Buy, with a price target consensus of $97.67.

### Related Stocks

- [IRON.US](https://longbridge.com/en/quote/IRON.US.md)
- [PCRX.US](https://longbridge.com/en/quote/PCRX.US.md)
- [RZLT.US](https://longbridge.com/en/quote/RZLT.US.md)
- [XENE.US](https://longbridge.com/en/quote/XENE.US.md)

## Related News & Research

- [Stifel Nicolaus Sticks to Their Buy Rating for Disc Medicine (IRON)](https://longbridge.com/en/news/285910632.md)
- [Disc Medicine (IRON) Projected to Post Earnings on Thursday](https://longbridge.com/en/news/284706493.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)
- [LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)](https://longbridge.com/en/news/286648209.md)
- [Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields](https://longbridge.com/en/news/286913304.md)